Biochemistry, Genetics and Molecular Biology
BRCA1
100%
Nested Gene
57%
Association
55%
Genotyping
42%
Mutation
39%
Age
31%
Haplotype
30%
Next Generation Sequencing
23%
Insulin-Like Growth Factor
23%
Bevacizumab
22%
Lactose
22%
Lactase
22%
Melting Point
21%
Germline
19%
Screening
18%
Prevalence
17%
Genetics
17%
Genetic Screening
17%
Dysplasia
16%
Overall Survival
16%
Single-Nucleotide Polymorphism
15%
DNA
15%
Computed Tomography
14%
Survival
14%
Gene Mutation
13%
Lysozyme
13%
MUTYH
13%
Quality Control
12%
Copy-Number Variation
12%
Amplicon
12%
Liquid
12%
Sequencing
12%
Sample
11%
Tyrosinase
11%
Angiotensin-Converting Enzyme
11%
Aging
11%
X Ray
11%
Detoxification
11%
Protein
11%
GSTT1
11%
Longevity
11%
Maturity
11%
Familial Hypercholesterolemia
11%
BRCA1
11%
Cystic Fibrosis Transmembrane Conductance Regulator
11%
Multiplex Ligation-Dependent Probe Amplification
10%
BRCA2
10%
Spectrum
9%
Allele
9%
Genetic Divergence
8%
Medicine and Dentistry
BRCA1
88%
Patient
63%
Gene
36%
Malignant Neoplasm
34%
Breast Cancer
32%
Haplotype
30%
Nodular Melanoma
27%
Age
27%
Somatomedin C
23%
Prematurity
22%
Ovarian Cancer
22%
Family
22%
Association
19%
Assay
19%
Lung Dysplasia
16%
Inpatient
16%
Pregnancy-Associated Plasma Protein A
16%
Quantitative Reverse Transcription Polymerase Chain Reaction
15%
Molecular Diagnosis
14%
Analysis
14%
Diseases
13%
Interleukin-6
13%
Pathogenicity
13%
Diagnosis
12%
Assessment
12%
Overall Survival
12%
Amplicon
12%
Laboratory
12%
Survival
11%
Copy Number Variation
11%
Sepsis
11%
Adrenal Hyperplasia
11%
Tyrosinase
11%
Krukenberg Tumor
11%
Dipeptidyl Carboxypeptidase
11%
Liver Cirrhosis
11%
Venous Pressure
11%
Blood
11%
Personalized Medicine
11%
Haplotype
11%
Diseases
11%
Neoadjuvant Chemotherapy
10%
Triple Negative Breast Cancer
10%
BRCA Mutation
10%
Epithelial Lining Fluid
10%
Serum
10%
False Positive Result
9%
RNA
8%
Biological Marker
8%
Multiplex Ligation Dependent Probe Amplification
7%
Nursing and Health Professions
Melanoma
19%
Patient
11%
Dipeptidyl Carboxypeptidase
11%
Sepsis
11%
Control
8%
Neonates
7%
Pilot Study
5%
Procedures
5%
